UGT1A1 and Insulin resistance: These results provide mechanistic evidence that bilirubin or altered bilirubin metabolism (e.g., partial UGT1A1 inhibitors) may be useful as a therapeutic approach to reduce obesity and improve insulin resistance and glucose tolerance.25